These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 33375317)

  • 1. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
    Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM
    Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
    Grunt TW; Mariani GL
    Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
    Han Y; Wang J; Wang Z; Xu B
    Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
    Wilks ST
    Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR.
    Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
    Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
    Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
    Lauring J; Park BH; Wolff AC
    J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
    ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
    Dey N; De P; Leyland-Jones B
    Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
    Narayanankutty A
    Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
    Zhang HP; Jiang RY; Zhu JY; Sun KN; Huang Y; Zhou HH; Zheng YB; Wang XJ
    Breast Cancer; 2024 Jul; 31(4):539-551. PubMed ID: 38630392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.